

Omnipod[®] 5

AUTOMATED INSULIN DELIVERY SIMPLIFIED.



Tubeless, automated insulin delivery for ages 2+ living with type 1 diabetes

Source: The Omnipod® 5 System was named 2022 Patient Choice Award Winner for preferred pump in the United States; Source: Seagrove Patient Perspectives Survey Report (304 Total Responses, 229 T1D, 75 T2D - 203 pumpers, 64 MDI, 37 on-MDI). Seagrove Partners, LLC Patient Perspectives Report, December 2022. Insulet data on file.

Simplify life with diabetes WITH TUBELESS AUTOMATED INSULIN DELIVERY.

Omnipod 5 System is the first tubeless automated insulin delivery system that integrates with the Dexcom G6 continuous glucose monitor. A brand new duo. Designed to deliver.





Pod shown without the necessary adhesive.

The tubeless Pod FUEL YOUR FREEDOM

Easily forgotten, but never left behind—the Pod has made Omnipod a concealable alternative to traditional pumps for years. And Omnipod 5 is no different, with each Pod providing up to 3 days, or 72 hours, of continuous, automated insulin delivery.*

- NO TUBES
- NO MULTIPLE DAILY INJECTIONS
- NO FINGERPRICKS NECESSARY[§]
- * Bolus for meals and corrections are still needed
- § Fingerpricks required for diabetes treatment decisions if symptoms or expectations do not match readings.



With automated control that IMPROVES OUTCOMES

SmartAdjust™ technology

is the brains behind the Omnipod® 5
Automated Insulin Delivery System. The system automatically increases, decreases, or pauses insulin delivery to your personal needs every five minutes, which may help to protect against highs and lows. You will still need to bolus for meals. With Omnipod 5, this is done with the Controller.

In a clinical study for people 6–70 years old,² Omnipod 5 and its SmartAdjust™ technology resulted in:

- LESS TIME SPENT IN LOW GLUCOSE
 During the day and overnight
- MORE TIME IN RANGE
 With 78% time in range overnight
- LOWER A1C
 Reduced by 0.7% without increasing time spent in low glucose
- Study in 240 people with T1D aged 6 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 in adults/adolescents = 64.7% vs. 73.9% and children = 52.5% vs. 68.0%. Brown et al. Diabetes Care (2021).
- Study in 80 people with T1D aged 2 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 = 57.2% vs. 68.1% SherrJL, et al. Diabetes Care (2022).

Get started AT ANY TIME

Whether you're looking to make the switch to the Omnipod 5 Automated Insulin Delivery System or just looking for more information, the next step is simple:

- Visit **omnipod.com** to check for more information
- Contact our Omnipod Specialist Team who can help answer your questions on 0800 011 6132, option 4

We'll do our part to make your life easier.



Scan here and get started with Omnipod 5.

The information in this leaflet should not be construed as medical advice and doesn't replace proper training.

Indications for use

The Omnipod 5 Insulin Pump (Pod) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The Omnipod 5 Insulin Pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The Omnipod 5 Insulin Pump is intended for single patient, home use and requires a prescription.

SmartAdjustTM technology is intended for use with compatible integrated continuous glucose monitors (iCGM) and and the Omnipod 5 Pod to automatically increase, decrease, and pause delivery of insulin based on current and predicted glucose values. SmartAdjustTM technology is intended for the management of type 1 diabetes mellitus in persons 2 years of age and older. SmartAdjustTM technology is intended for single patient use and requires a prescription.

The Omnipod 5 SmartBolus Calculator is software intended for the management of diabetes in persons aged 2 and older requiring rapid-acting U-100 insulin. The Omnipod 5 SmartBolus Calculator calculates a suggested bolus dose based on user-entered carbohydrates, most recent sensor glucose value (or blood glucose reading if using fingerstick), rate of change of the sensor glucose (if applicable), insulin on board (IOB), and programmable correction factor, insulin to carbohydrate ratio, and target glucose value. The Omnipod 5 SmartBolus Calculator is intended for single patient, home use and requires a prescription.

The Omnipod 5 System is NOT recommended for people who:

- · are unable to monitor glucose as recommended by their healthcare provider
- are unable to maintain contact with their healthcare provider
- are unable to use the Omnipod 5 System according to instructions
- are taking hydroxyurea as it could lead to falsely elevated CGM values and result in over-delivery of insulin that can lead to severe hypoglycemia
- do NOT have adequate hearing and/or vision to allow recognition of all functions of the Omnipod 5 System, including alerts, alarms, and reminders

Device components including the Pod, CGM transmitter, and CGM sensor must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment. In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to MRI, CT, or diathermy treatment can damage the components.

Warning: SmartAdjust™ technology should NOT be used by anyone under the age of 2 years old. SmartAdjust™ technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population.

Compatible insulins

The Omnipod 5 System is compatible with the following U-100 insulins: NovoLog® / Novorapid®, Humalog®, and Admelog® / Insulin lispro Sanofi®.

©2023 Insulet Corporation. Omnipod, the Omnipod logo, and SmartAdjust are trademarks or registered trademarks of Insulet Corporation. All rights reserved. Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. and used with permission. The Bluetooth's word marks and logos are registered trademarks owned by the Bluetooth SIG, Inc. and any use of such marks by Insulet Corporation is under license. The use of third-party trademarks does not constitute an endorsement or imply a relationship or other affiliation.

Insulet Netherlands BV Stadsplateau 7, 3521 AZ Utrecht, Netherlands

INS-0HS-04-2023-00083 V1

3 simple parts



OMNIPOD 5 CONTROLLER



DEXCOM G6*

*Pod and Dexcom G6 shown without necessary adhesive. A separate prescription is required for the Dexcom G6 CGM. The Dexcom G6 is sold separately and must be used with the Dexcom G6 mobile app. The Dexcom G6 receiver is not compatible with the Omnipod 5 System.